Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amicus, Biogen enter multi-year agreement in Parkinson's

Executive Summary

Just a day after signing its fourth antisense neurology deal with Isis Pharmaceuticals, Biogen Idec Inc. penned a multi-year agreement with rare disease drug company Amicus Therapeutics Inc. for the discovery, development, and commercialization of small molecules for Parkinson's disease (PD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies